SM 213 Thrombotic Microangiopathies Flashcards

1
Q

What are thrombotic microangiopathies?

A

TMA’s are a heterogeneous group of disorders characterized clinically by a triad of:

Microangiopathic hemolytic anemia
Thrombocytopenia
Organ Injury

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is seen on slides in TMA?

A

Fragments of RBC’s called schistocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What area of the Nephron is suspectible to TMA?

A

Glomerular microvasculature

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the 3 types of TMA’s?

A

TTP = Thrombotic Trombocytic purpura
HUS = Hemolytic Uremic Syndromes
Other TMA’s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the two types of HUS?

A

D+HUS (Diarrhea due to Shigatoxin) and Atypical HUS (Due to defect in Complement Regulatory Proteins)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What can cause the “other” TMA’s?

A

Pre-eclampsia and anti-VEGF drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is found in the blood of patients with TTP?

A

Patients with TTP have large circulating multimers of vWF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the trigger for TTP?

A

Endothelial cells releasing multimers of vWF, normally chopped up by ADAMTS13 (now deficient)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Why do clots of vWF form and clog microvasculature in TTP?

A

Low enzymatic activity of ADAMTS13 either due to birth defect or due an auto-antibody to ADAMTS13

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What forms clots in TTP?

A

Multimers of vWF forming microclots

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are symptoms of TTP?

A

Schistocytes (fragments of RBC’s)
Low platelets
Fever

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is used to diagnose TTP?

A

Measuring activity of ADAMTS13 and finding low activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Explain the pathophysiology of HUS?

A

Thrombi form in the small capillaries and arterioles leading to ischemia to the Glomeruli

Due to either Shigatoxin or CRP deficiencies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What toxin is associated with HUS?

A

Shiga-toxin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What strain of E. coli causes HUS?

A

O157:H7 - the shiga-toxin producing strain of E. coli that produces HUS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Which population is mostly effected by HUS?

A

Pediatric populations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How does Shiga-toxin work?

A

Ingest bacteria
Toxin enters the circulation
Toxin binds to Gb3 receptor on glomerulal endothelial cells
Platelet clots form

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Why do children tend to be effected by Shiga-toxin?

A

More expression of the Gb3 receptor = more targets for Shiga-toxin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Can EAEC cause HUS?

A

Yes, if they acquire the shigatoxin gene, as was the case in Germany in 2011

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What causes atypical HUS?

A

By definition, HUS not caused by Shigatoxin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Which is more common, aHUS or shigatoxin-mediated HUS?

A

Shigatoxin mediated HUS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Is atypical HUS heritable?

A

Yes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What part of the immune system is dysregulated in aHUS?

A

Abnormalities in complement regulation cause aHUS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What’s worse, aHUS or normal HUS?

A

aHUS, both in terms of mortality and complications in surviving patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What are the 3 complement pathways?

A

Classical - immune complex
Lectin - microbes
Alternatives - implicated in HUS

26
Q

What is the complement system?

A

An ancient defense system

27
Q

Where do the complement pathways converge?

A

All 3 pathways converge on C5b-9

28
Q

When is the alternative complement pathway active?

A

Always, but it is regulated by other proteins

29
Q

How is the alternative complement pathway altered in aHUS?

A

A mutation in a protein(s) that inhibit the alternative complement pathway or antibodies against these proteins lead to overactivity of the aHUS

Causes endothelial cell damage

30
Q

What type of cells are damaged by aHUS?

A

Endothelial cells are damaged by constititutive alternative complement pathway activation, leading to generation of more immune signals

31
Q

Why do some patients with a mutation that predisposes aHUS not develop aHUS?

A

Two hit hypothesis

32
Q

Which form of TMA has normal ADAMTS13?

A

HUS

33
Q

Which form of TMA has low ADAMTS13?

A

TTP

34
Q

What bacteria other than E. coli can cause HUS?

A

Strep. pneumoniae - neuraminidase can damage the endothelium

35
Q

What nutrient deficiency can predispose HUS?

A

B12 deficiency

36
Q

Why is the kidney particularly susceptible to thrombotic injury?

A

Extremely high vascular flow, since it filters the entire circulation several times every week

37
Q

How are Podocytes connected to fenestrated endothelium in a healthy kidney?

A

Podocytes are normally intimately associated with underlying fenestrated endothelium, forming interdigated slits with their foot processes

38
Q

What is the most potent growth factor for endothelial cells, and what cells make it?

A

VEGF is the most potent growth factor for endothelial cells, and it’s made by Podocytes at high levels

39
Q

Where are VEGF receptors found?

A

The Glomerular basement membrane contains lots of VEGF receptors, but they are also found throughout the body

40
Q

Why can’t full VEGF knockouts be used in a mouse model?

A

The mouse dies during embryonic development because VEGF is needed for embryonic development

41
Q

How are VEGF knockout mice created?

A

Only knockout VEGF in the podocyte cells so it otherwise develops normally

42
Q

What is the role of VEGF in TMA?

A

VEGF protects the glomerular capillary from TMA by promoting eNOS activity as well as protecting against damage to the glomerular endothelium

43
Q

What is the pathopneumonic finding for TMA?

A

Endotheliosis

44
Q

How was VEGF studied in adult filtering glomeruli?

A

Anti-cancer that act as VEGF inhibitors (antibodies) can knockout VEGF to see the effect of VEGF on adult filtering glomeruli

Caused endotheliosis

45
Q

What were the side effects of VEGF blocker drugs?

A

Dose-dependent proteinuria that could even be nephrotic range

Severe HTN - consistent with a RAAS reflex response to decreased perfusion at Glomeruli

46
Q

What class of drugs can cause TMA?

A

VEGF inhibitors

47
Q

What does endotheliosis cause?

A

Bloodless glomeruli (lacking blood flow) with fibrous material deposited in and around the capillary endothelium

48
Q

Why do VEGF blockers cause endotheliosis?

A

The capillaries in the glomeruli are filled with microthrombi due to loss of both eNOS activity and the protective effects VEGF has on the glomerular basement membrane, destroying the blood supply to the glomeruli

49
Q

What is the role of VEGF in the glomeruli with respect ot TMA?

A

VEGF prevents clotting the Glomeruli

50
Q

Do anti-VEGF agents affect every patient?

A

Nope, only a very small subset

51
Q

What form of TMA effects pregnant women?

A

Pre-eclampsia

52
Q

How does Pre-eclampsia start?

A

In the placenta
Spiral artery needs to remodel
In pre-eclampsia, artery remodelling is flawed
Leads to Hypoxia
VEGF Decoy (SLFT1) is secreted into the bloodstream
VEGF Decoy prevents binding of VEGF to the VEGF Receptor, causing TMA

53
Q

How does pre-eclampsia cause TMA?

A

In pre-eclampsia, hypoxia leads to secretion of a VEGF decoy (SLFT1) into the neonatal bloodstream that prevents VEGF from binding VEGF Receptors in the neonatal glomeruli, causing endotheliosis and TMA

54
Q

What are the 3 protective pathways against TMA?

A

ADAMTS13
Complement Regulatory Proteins
VEGF-VEGF Receptor signaling

55
Q

What defect is aHUS associated with?

A

A defective complement regulatory pathway can cause aHUS

56
Q

How is TTP treated?

A

Infuse plasma contained ADAMTS13

Rituximab to inhibit formation of Antibodies against B cells

57
Q

How is aHUS treated?

A

Infuse the missing complement regulatory protein via plasma contain the missing protein
Add Eculizamab, a C5 inhibitor

58
Q

How does Eculizamab treat aHUS?

A

Eculizamab is a C5 inhibitor, which blocks the common part of the complement pathway, to prevent thrombi form forming in aHUS

59
Q

How should anti-VEGF TMA be treated?

A

Discontinue the drug and never start it again

60
Q

How should pre-eclampsia TMA be treated?

A

Deliver the baby

Remove the VEGF decoy from the baby via column

61
Q

What is the classic TMA patient?

A

A young woman with neurological symptoms, low platelet count, and shcitocytes on blood smear

62
Q

What are Schistocytes?

A

Fragments of RBC’s